

14 October 2022

Market Announcements Office
ASX Limited
20 Bridge Street
Sydney NSW 2000

Dear Sir / Madam

Bod Australia Limited (ASX: BOD)
Notice under section 708A(5) of the Corporations Act 2001 (Cth)

This notice is given by Bod Australia Limited (ASX:BOD) ACN 601 225 441 (the **Company** or **BOD**) under section 708(5)(e) of the *Corporations Act 2001* (Cth) (**Act**).

BOD advises that it has issued the following fully paid BOD ordinary shares (**Shares**):

1. On 13 October 2022, the Company issued 1,250,000 Shares pursuant to the Underwriting Agreement with Mr David Baker in relation to the pro rata, non-accelerated, non-renounceable entitlement offer announced on 1 September 2022.
2. On 14 October 2022, the Company issued 3,125,000 Shares as consideration for future marketing services to be provided to the Company.

For the purposes of section 708A(6) of the Act, BOD advises that:

1. The Shares referred to above were offered for issue without disclosure under Part 6D.2 of the Act.
2. This notice is being given under section 708A(5)(e) of the Act.
3. As at the date of this notice Bod has complied with:
 - a. the provisions of Chapter 2M of the Corporations Act as they apply to BOD; and
 - b. sections 674 and 674A of the Act.
4. As at the date of this notice, there is no excluded information of the type referred to in sections 708A(7) and 708A(8) of the Corporations Act.

Authorised for release by the Company Secretary of BOD.

ENDS

Further Information

Investors:

Stephen Kelly
Company Secretary
Info@bodaustralia.com
+61 415 719 695

About Bod Australia

Media:

Henry Jordan
Six Degrees Investor Relations
Henry.jordan@sdir.com.au
+61 431 271 538

Bod Australia Limited (ASX:BOD) Bod is a cannabis focused drug development and product innovation company.

CONTACT

Level 1, 377 New South Road, Double Bay NSW 2028 **T** +61 2 9199 5018 **E** info@bodscience.com **W** bodscience.com

Bod is focused on progressing R&D and a defined clinical trial pathway to commercialise and deliver premium, scientifically proven and trusted products for the consumer and medical markets.

The company has a number of existing partnerships with large corporate groups and collaborations with leading research partners to advance the use of CBD.

For more information on BOD please visit <http://bodaustralia.com/>

IMPORTANT INFORMATION

This announcement has been prepared for publication in Australia and may not be released to US wire services or distributed in the United States. This announcement does not constitute an offer to sell, or a solicitation of an offer to buy, securities in the United States or any other jurisdiction. Any securities described in this announcement have not been, and will not be, registered under the US Securities Act of 1933 and may not be offered or sold in the United States except in transactions exempt from, or not subject to, registration under the US Securities Act and applicable US state securities laws.

CONTACT

Level 1, 377 New South Road, Double Bay NSW 2028 **T** +61 2 9199 5018 **E** info@bodscience.com **W** bodscience.com